OncoSec Medical Inc Short ratio
What is the Short ratio of OncoSec Medical Inc?
The Short ratio of OncoSec Medical Inc is 0.32
What is the definition of Short ratio?
Short ratio is the number of shares sold short divided by the average daily volume.
= short interest / average daily volume
Short ratio is calculated by dividing the number of shares sold short by the average daily trading volume, generally over the last 30 trading days. The ratio represents the number of days it takes short sellers on average to repurchase all the borrowed shares. The ratio is used by both fundamental and technical traders to identify trends.
The percentage represents the number of days it takes short sellers on average to repurchase all the borrowed shares. Short selling is the practice of selling securities or other financial instruments that are not currently owned, and subsequently repurchasing them. In the event of an interim price decline, the short seller profits, since the cost of (re)purchase is less than the proceeds received upon the initial (short) sale. Conversely, the short position closes out at a loss if the price of a shorted instrument rises prior to repurchase. A high short ratio can be an indicator that there will be some buying pressure on the security that would increase its price.
Short ratio of companies in the Health Care sector on NASDAQ compared to OncoSec Medical Inc
What does OncoSec Medical Inc do?
oncosec is a san diego-based biotechnology company pioneering new technologies to stimulate the body’s immune system to target and attack cancer. through our proprietary technology, we hope to deliver safer and more effective cancer treatments that can provide long-term benefits for patients. our technology, immunopulse™, is designed to enhance the local delivery and uptake of dna-based immune-targeting agents, such as il-12. clinical trials of immunopulse™ il-12 demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various skin cancers as well as the potential to initiate a systemic immune response. our lead program, immunopulse™ il-12, is currently in phase ii development for several indications, including metastatic melanoma, squamous cell carcinoma of the head and neck, and triple-negative breast cancer. to date, study results have laid the groundwork for the expansion into new dna-encoded therapeutic candidates and tumor indications. we ar
Companies with short ratio similar to OncoSec Medical Inc
- Yangtze River Port and Logistics Ltd has Short ratio of 0.31
- Jupai Ltd has Short ratio of 0.31
- TORC Oil & Gas has Short ratio of 0.31
- Zhangmen Education has Short ratio of 0.31
- Nicola Mining has Short ratio of 0.31
- Invesco Municipal Opportunity Trust has Short ratio of 0.31
- OncoSec Medical Inc has Short ratio of 0.32
- Last Mile has Short ratio of 0.33
- Bitcoin Well Inc has Short ratio of 0.33
- Euro Manganese has Short ratio of 0.33
- Quebec Precious Metals has Short ratio of 0.33
- Collective Growth has Short ratio of 0.33
- FRNT has Short ratio of 0.33